Compare GSK plc (GSK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M). The key difference: GSK plc is far larger — about 95.5× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and GSK plc pays a 3.9% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 57 Days on average.
| GSK | QDTE | |
|---|---|---|
Market Cap | $91.88B | $962.24M |
Volume | 7,730,529 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $36.60 |
52-Week Low | $43.24 | $26.85 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.50, down 1.3% today amid bearish technical signals. The ETF generates weekly income through covered call strategies on Nasdaq-100 components, with recent distributions ranging from $0.11-$0.28. Technical indicators show mixed signals with overall bearish momentum, while fundamental data remains limited for this specialized income-focused product.
The outlook remains cautious as declining volatility pressures distribution yields, with recent payouts suggesting a more sustainable 24-31% annualized yield versus the trailing 43%. Key risks include NAV erosion from return of capital and underperformance in bull markets due to capped upside potential from daily call writing strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
